Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market (repealed)
Print Options
PrintThe Whole
Directive
PrintThe Whole
Annex
PrintThe Whole
Division
PrintThis
Division
only
Status:
EU Directives are published on this site to aid cross referencing from UK legislation. Since IP completion day (31 December 2020 11.00 p.m.) no amendments have been applied to this version.
[V. EFFECTS ON HUMAN HEALTH U.K.
TIER I U.K.
5.1. Basic information U.K.
5.1.1. Medical data U.K.
5.1.2. Medical surveillance on manufacturing plant personnel U.K.
5.1.3. Sensitisation/allergenicity observations U.K.
5.1.4. Direct observation, e.g. clinical cases U.K.
5.2. Basic studies U.K.
5.2.1. Sensitisation U.K.
5.2.2. Acute toxicity, pathogenicity, and infectiveness U.K.
5.2.2.1. Acute oral toxicity, pathogenicity and infectiveness U.K.
5.2.2.2. Acute inhalation toxicity, pathogenicity and infectiveness U.K.
5.2.2.3. Intraperitoneal/subcutaneous single dose U.K.
5.2.3. In vitro genotoxicity testing U.K.
5.2.4. Cell culture study U.K.
5.2.5. Information on short-term toxicity and pathogenicity U.K.
5.2.5.1. Health effects after repeated inhalatory exposure U.K.
5.2.6. Proposed treatment: first aid measures, medical treatment U.K.
5.2.7. Any pathogenicity and infectiveness to humans and other mammals under conditions of immunosuppression U.K.
END OF TIER I U.K.
TIER II U.K.
5.3. Specific toxicity, pathogenicity and infectiveness studies U.K.
5.4. Genotoxicity — In vivo studies in somatic cells U.K.
5.5. Genotoxicity — In vivo studies in germ cells U.K.
END OF TIER II U.K.
5.6. Summary of mammalian toxicity, pathogenicity and infectiveness and overall evaluation] U.K.
Back to top